Yesterday, Nov. 3, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $9.84 to $10,914,626.52.

Highlighted Stocks Traded by Insiders:

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 2,107 shares at $25.75 on Nov. 3, 2015. Following this transaction, the Shareholder owned 803,253 shares meaning that the stake was reduced by 0.26% with the 2,107-share transaction.

The shares most recently traded at $25.28, down $0.47, or 1.84% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 32,235
  • 12-Week # shares sold: 93,951
  • 24-Week # shares sold: 190,624

The average volume for Village Super Market has been 25,800 shares per day over the past 30 days. Village Super Market has a market cap of $257.9 million and is part of the services sector and retail industry. Shares are down 4.2% year-to-date as of the close of trading on Tuesday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 3.81%. The company has a P/E ratio of 12.1. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gladstone Commercial (GOOD) - FREE Research Report

Cutlip Robert G, who is President at Gladstone Commercial, bought 1,700 shares at $15.95 on Nov. 3, 2015. Following this transaction, the President owned 23,900 shares meaning that the stake was boosted by 7.66% with the 1,700-share transaction.

The shares most recently traded at $16.17, up $0.22, or 1.38% since the insider transaction. Historical insider transactions for Gladstone Commercial go as follows:

  • 4-Week # shares bought: 500
  • 12-Week # shares bought: 4,000
  • 24-Week # shares bought: 10,250

The average volume for Gladstone Commercial has been 123,000 shares per day over the past 30 days. Gladstone Commercial has a market cap of $355.9 million and is part of the financial sector and real estate industry. Shares are down 6.29% year-to-date as of the close of trading on Tuesday.

Gladstone Commercial Corporation operates as a real estate investment trust (REIT) in the United States. It engages in investing in and owning net leased industrial and commercial real properties, and making long-term industrial and commercial mortgage loans. The stock currently has a dividend yield of 9.3%. The company has a P/E ratio of 84.9. Currently, there is 1 analyst who rates Gladstone Commercial a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GOOD - FREE

TheStreet Quant Ratings rates Gladstone Commercial as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, unimpressive growth in net income and feeble growth in its earnings per share. Get the full Gladstone Commercial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Neuralstem (CUR) - FREE Research Report

Johe Karl, who is Chief Scientific Officer at Neuralstem, sold 25,000 shares at $1.17 on Nov. 3, 2015. Following this transaction, the Chief Scientific Officer owned 876,304 shares meaning that the stake was reduced by 2.77% with the 25,000-share transaction.

The shares most recently traded at $1.24, up $0.07, or 5.31% since the insider transaction. Historical insider transactions for Neuralstem go as follows:

  • 4-Week # shares bought: 14,250
  • 4-Week # shares sold: 75,000
  • 12-Week # shares bought: 14,250
  • 12-Week # shares sold: 150,000
  • 24-Week # shares bought: 14,250
  • 24-Week # shares sold: 150,000

The average volume for Neuralstem has been 425,000 shares per day over the past 30 days. Neuralstem has a market cap of $111.1 million and is part of the health care sector and drugs industry. Shares are down 55.51% year-to-date as of the close of trading on Tuesday.

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. Currently, there are 2 analysts who rate Neuralstem a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CUR - FREE

TheStreet Quant Ratings rates Neuralstem as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Neuralstem Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.